Reference
1. Sharma, S.R., X. Gonda, and F.I. Tarazi, Autism Spectrum Disorder: Classification, diagnosis and therapy. Pharmacol Ther, 2018. 190: p. 91-104.
2. Fung, L.K., et al., Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis. Pediatrics, 2016. 137 Suppl 2: p. S124-35.
3. Persico, A.M., A. Ricciardello, and F. Cucinotta, The psychopharmacology of autism spectrum disorder and Rett syndrome. Handb Clin Neurol, 2019. 165: p. 391-414.
4. Hiemke, C., et al., Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry, 2018. 51(1-02): p. 9-62.
5. Klampfl, K., et al., Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry, 2010. 43(2): p. 58-65.
6. Taurines, R., et al., Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. J Neural Transm (Vienna), 2022. 129(5-6): p. 689-701.
7. Kloosterboer, S.M., et al., Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder. Br J Clin Pharmacol, 2021. 87(3): p. 1069-1081.
8. Hermans, R.A., et al., Therapeutic Drug Monitoring to Optimize Risperidone Treatment in Children with Autism Spectrum Disorder. Ther Drug Monit, 2024. 46(2): p. 259-264.
9. Bergstrand, M., et al., Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J, 2011. 13(2): p. 143-51.
10. van der Esch, C.C.L., et al., Risk factors and pattern of weight gain in youths using antipsychotic drugs. Eur Child Adolesc Psychiatry, 2021. 30(8): p. 1263-1271.
11. Busner, J. and S.D. Targum, The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont), 2007. 4(7): p. 28-37.
12. Karatza, E., et al., External Evaluation of Risperidone Population Pharmacokinetic Models Using Opportunistic Pediatric Data. Front Pharmacol, 2022. 13: p. 817276.
13. Hermans, R.A., et al., The effect of therapeutic drug monitoring of risperidone and aripiprazole on weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of an international multicentre randomised controlled trial. BMC Psychiatry, 2022. 22(1): p. 814.
14. Hermans, R.A., et al., External validation of a therapeutic window for risperidone in children with autism spectrum disorder. Br J Clin Pharmacol, 2025. 91(10): p. 3009-3015.